Worth reading
70In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Contents of this document
Financial results presentationFirst quarter of the fiscal year ending March 202711 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥8,848 million+3.5%
Operating profit¥618 million-2.0%
Ordinary income¥517 million-14.9%
Net income¥336 million-11.9%
Gross Profit Margin46.9 %
Operating profit margin7 %
Selling, general and administrative expenses¥3,533 million
Results for the three months of the current quarterRevenue: ¥8,848 million; gross profit: ¥4,151 million; operating profit: ¥618 million; ordinary profit: ¥517 million; profit attributable to owners of the parent: ¥336 million
Full-year earnings forecast
Net Sales
¥37,000 million
Operating profit
¥2,200 million
Ordinary income
¥1,750 million
Profit attributable to owners of the parent
¥1,350 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales23.9%
Operating profit28.1%
Ordinary income29.6%
Profit attributable to owners of the parent24.9%
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Revenue increase+¥301 million
- Increase in gross profit+¥303 million
- Increase in SG&A expenses-¥315 million
- Decrease in non-operating income-¥8 million
- Increase in non-operating expenses-¥69 million
- Decrease in extraordinary income-¥23 million
- Increase in extraordinary losses-¥2 million
- Decrease in taxes and other expenses+¥70 million
New initiatives
- Change the investment amount for the Phase 2 plan for Building 4 of the Konosu Research Institute from ¥11.59 billion to ¥7.55 billion and production capacity from approximately 10.5 million lenses per month to approximately 3.5 million lenses per month
- Launch the Belmie TORIC colored contact lens
- Begin a demonstration test for the chemical recycling of empty blister packs
- Establish a China Sales Department to promote sales growth within China
Key KPIsA metric the company considers important as a management benchmark.
- EBITDA¥1,777 millionYear on year against the same period last year+¥299 million
- EBITDA margin20.1 %Year on year against the same period last year+2.8 percentage points
- Overseas revenue14.7 Hundreds of millions of yenYear on year against the same period last year+19.3%
- Orthokeratology lens revenue¥255 millionYear on year against the same period last year+9.5%
- Debt dependency ratio42.8 %
- Equity ratio28.9 %
Segment results
- Contact Lens BusinessFirst-quarter revenue for the fiscal year ending March 2027¥8,679 millionNet sales in the same period of the previous year¥8,385 millionYear-on-year change in amount¥294 million
- Care productsFirst-quarter revenue for the fiscal year ending March 2027¥153 millionNet sales in the same period of the previous year¥141 millionYear-on-year change in amount¥12 million
- OtherFirst-quarter revenue for the fiscal year ending March 2027¥16 millionNet sales in the same period of the previous year¥20 millionYear-on-year change in amount¥-4 million
Medium-term management plan targets
Target fiscal yearFiscal year ending March 2027
Net Sales
370 Hundreds of millions of yen
Operating profit
22 Hundreds of millions of yen
EBITDA
69.5 Hundreds of millions of yen
ROE
6.9 %
Consolidated revenue of ¥50 billionMedium- to Long-Term Targets
Financial targets
ROE
Target value6.9 %
Number of stores and locations
End of period8 sales offices and 11 other outposts (as of the end of March 2026)
Number of employees
Number of Employees1,489 People
Record dateEnd of March 2026
Capital expenditures
75.5 Hundreds of millions of yen
Annual Dividend
Annual dividend per share¥15
Payout ratio
30～40
| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | First quarter of the fiscal year ending March 2027 |
| Net Sales | ¥8,848 million (YoY +3.5%) |
| Operating profit | ¥618 million (YoY -2.0%) |
| Ordinary income | ¥517 million (YoY -14.9%) |
| Net income | ¥336 million (YoY -11.9%) |
| Gross Profit Margin | 46.9 % |
| Operating profit margin | 7 % |
| Selling, general and administrative expenses | ¥3,533 million |
| Results for the three months of the current quarter | Revenue: ¥8,848 million; gross profit: ¥4,151 million; operating profit: ¥618 million; ordinary profit: ¥517 million; profit attributable to owners of the parent: ¥336 million |
| Full-year earnings forecast | Net Sales ¥37,000 million / Operating profit ¥2,200 million / Ordinary income ¥1,750 million / Profit attributable to owners of the parent ¥1,350 million |
| Progress against full-year forecast | Net Sales 23.9% / Operating profit 28.1% / Ordinary income 29.6% / Profit attributable to owners of the parent 24.9% |
| Segment results | Segment Contact Lens Business / First-quarter revenue for the fiscal year ending March 2027 ¥8,679 million / Net sales in the same period of the previous year ¥8,385 million / Year-on-year change in amount ¥294 million / Profit Not disclosed, Segment Care products / First-quarter revenue for the fiscal year ending March 2027 ¥153 million / Net sales in the same period of the previous year ¥141 million / Year-on-year change in amount ¥12 million / Profit Not disclosed, Segment Other / First-quarter revenue for the fiscal year ending March 2027 ¥16 million / Net sales in the same period of the previous year ¥20 million / Year-on-year change in amount ¥-4 million / Profit Not disclosed |
| Breakdown of Factors Affecting the Change | Factors Revenue increase / Amount +¥301 million, Factors Increase in gross profit / Amount +¥303 million, Factors Increase in SG&A expenses / Amount -¥315 million, Factors Decrease in non-operating income / Amount -¥8 million, Factors Increase in non-operating expenses / Amount -¥69 million, Factors Decrease in extraordinary income / Amount -¥23 million, Factors Increase in extraordinary losses / Amount -¥2 million, Factors Decrease in taxes and other expenses / Amount +¥70 million |
| Key KPIs | Indicator name EBITDA / Value ¥1,777 million / Year on year against the same period last year +¥299 million, Indicator name EBITDA margin / Value 20.1 % / Year on year against the same period last year +2.8 percentage points, Indicator name Overseas revenue / Value 14.7 Hundreds of millions of yen / Year on year against the same period last year +19.3%, Indicator name Orthokeratology lens revenue / Value ¥255 million / Year on year against the same period last year +9.5%, Indicator name Debt dependency ratio / Value 42.8 % / Year on year against the same period last year Not disclosed, Indicator name Equity ratio / Value 28.9 % / Year on year against the same period last year Not disclosed |
| Number of stores and locations | End of period 8 sales offices and 11 other outposts (as of the end of March 2026) / Number of store openings and closures during the period Not disclosed |
| Number of employees | Number of Employees 1,489 People / Record date End of March 2026 / Changes during the period and hiring plan Not disclosed |
| Medium-term management plan targets | Target fiscal year Fiscal year ending March 2027 / Net Sales 370 Hundreds of millions of yen / Operating profit 22 Hundreds of millions of yen / EBITDA 69.5 Hundreds of millions of yen / ROE 6.9 % / Consolidated revenue of ¥50 billion Medium- to Long-Term Targets |
| Financial targets | ROE Target value 6.9 % / Actual value Not disclosed / Equity ratio Not disclosed / ROIC Not disclosed / Debt-to-equity ratio Not disclosed |
| Annual Dividend | Annual dividend per share ¥15 / Interim Not disclosed / End of period Not disclosed |
| Payout ratio | 30～40 |
| Capital expenditures | 75.5 Hundreds of millions of yen |
| New initiatives | Change the investment amount for the Phase 2 plan for Building 4 of the Konosu Research Institute from ¥11.59 billion to ¥7.55 billion and production capacity from approximately 10.5 million lenses per month to approximately 3.5 million lenses per month, Launch the Belmie TORIC colored contact lens, Begin a demonstration test for the chemical recycling of empty blister packs, Establish a China Sales Department to promote sales growth within China |
Items this document does not state (8)
Self-assessment against the planUnit price and quantity metricsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue and gross profit increased due to the recovery in sales of toric and multifocal lenses, expanded sales of the AirGrade series, and growth in cross-border e-commerce sales in China. Operating profit declined due to higher R&D expenses associated with clinical trials, personnel expenses resulting from workforce expansion and improved employee compensation, advertising expenses, and other costs. The Phase 2 plan for Building 4 was changed following a comprehensive review of progress on the production-capacity expansion plan and the efficiency of capital investment, in order to optimize the investment program.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.